A Phase 3 Study Comparing Sacituzumab Govitecan Versus Standard Treatment in People With Advanced Endometrial Cancer

Full Title

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Purpose

Researchers are comparing sacituzumab govitecan to standard treatment in people with endometrial cancer. The people in this study have endometrial cancer that came back or keeps growing after chemotherapy and immunotherapy.

Sacituzumab govitecan is an antibody that binds to proteins on cancer cells. Once there, it releases a drug that enters the cells and kills them. Sacituzumab govitecan is given intravenously (by vein).

If you take part in this study, you will be randomly assigned to get one of these treatments:

• Sacituzumab govitecan.
• Standard treatment with doxorubicin or paclitaxel, given intravenously.

Who Can Join

To join this study, there are a few conditions. You must:

• Have endometrial cancer that came back or keeps growing even though you had chemotherapy and immunotherapy.
• Have had no more than 3 prior regimens of anti-cancer medications.
• Have recovered from the serious side effects of previous treatments before getting the study therapy.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Vicky Makker’s office at 646-888-4224.